薬剤排出ステントを識別する際の遅いルメン損失の強度,可変観察およびランダム化試験における可変観察およびランダム化試験における強度
Laura Mauri1, E John Orav, Susana C Candia
1Brigham and Women's Hospital, Boston, MA 02116, USA. lmauri1@partners.org
Circulation
|November 4, 2005
まとめ
ステントの遅い損失の平均は,研究におけるステントの性能を評価するために,レステノーシス比率よりも信頼性の高い指標です. このメトリックは,薬剤排出ステントプラットフォームをより良く区別し,早期の評価に役立ちます.
科学分野:
- 心血管研究 循環器科の研究
- 医療機器技術 医療機器技術について
- 臨床試験の方法論について
背景:
- ステント試験におけるレステノーシス率は,ケースミックスによる差異により異なる.
- インステントの遅い損失は,より安定したレステノシス傾向推定値として提案されています.
研究 の 目的:
- 平均インステント遅延損失が,研究間のステントパフォーマンスを比較するために,バイナリレステノシス比率よりも信頼性の高いメトリックであるかどうかを評価する.
- 初期段階の研究における薬物排出ステントの評価のための最適なエンドポイントを決定する.
主な方法:
- 薬物放出および裸金属ステントを含む46件の試験の分析.
- 遅い損失と標的の損傷再血管化 (TLR) のイントラクラス相関係数 (rho) の比較.
- 糖尿病の罹患率と病変の長さに基づく遅い喪失の標準化.
主要な成果:
- 平均遅い損失の増加は,より高い標的病変再血管化 (TLR) 率 (P<0.001) と相関する.
- 遅い損失は,TLR (rho=0.71 vs. 0.22) と比較して,ステントのクラス (薬物排出 vs. 裸金属) の間の優れた差別を示しました.
- また,遅いステント喪失は,個々のステント比較においてより優れた差別性を示した (rho=0.68 vs. 0.19).
結論:
- ステントの遅い損失の平均は,ステントプラットフォームの間でレステノシス傾向を差別するバイナリレステノシス比率よりも信頼性が高い.
- 遅い損失は,早期の非ランダム化研究では,薬剤排出ステントの評価のための最適なエンドポイントとして機能する可能性があります.
関連する概念動画
Measurement of Bioavailability: Pharmacokinetic Methods
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
Drug Product Stability
The long-term stability of drug products is critical to ensuring their quality, safety, and effectiveness over time. Stability directly influences a product's ability to maintain its intended characteristics, ensuring it performs as expected during its intended shelf life. Key attributes such as drug potency, impurities, dissolution, and other physicochemical measures of performance are tested to assess stability. These parameters indicate how well the product retains its quality over time and...
Dosage Regimen: Multiple Oral Dosage
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...


